The Journal of Allergy and Clinical Immunology
Volume 122, Issue 6 , Pages 1087-1096 , December 2008

Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: Current status and critical needs

  • Linda M. Griffith, MD, PhD

      Affiliations

    • Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
    • ,
  • Morton J. Cowan, MD

      Affiliations

    • Pediatric Blood and Marrow Transplant Division, UCSF Children's Hospital, San Francisco, Calif
    • ,
  • Donald B. Kohn, MD

      Affiliations

    • Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, University of Southern California, Los Angeles, Calif
    • ,
  • Luigi D. Notarangelo, MD

      Affiliations

    • Division of Immunology, Children's Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Jennifer M. Puck, MD

      Affiliations

    • Department of Pediatrics, Institute for Human Genetics, University of California San Francisco, San Francisco, Calif
    • ,
  • Kirk R. Schultz, MD

      Affiliations

    • Pediatric Blood and Marrow Transplantation, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Rebecca H. Buckley, MD

      Affiliations

    • Pediatric Allergy and Immunology, Duke University School of Medicine, Durham, NC
    • ,
  • Mary Eapen, MD, MS

      Affiliations

    • Center for International Blood and Marrow Transplant Research/Medical College of Wisconsin, Milwaukee, Wis
    • ,
  • Naynesh R. Kamani, MD

      Affiliations

    • Blood and Marrow Transplantation and Immunology, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC
    • ,
  • Richard J. O'Reilly, MD

      Affiliations

    • Departments of Pediatrics and Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Robertson Parkman, MD

      Affiliations

    • Division of Research Immunology/BMT, Childrens Hospital Los Angeles, Los Angeles, Calif
    • ,
  • Chaim M. Roifman, MD, FRCPC

      Affiliations

    • Division of Immunology and Allergy, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Kathleen E. Sullivan, MD, PhD

      Affiliations

    • Pediatric Immunology, Children's Hospital of Philadelphia, University of Pennsylvania, Pennsylvania, Pa
    • ,
  • Alexandra H. Filipovich, MD

      Affiliations

    • Pediatric Clinical Immunology, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
    • ,
  • Thomas A. Fleisher, MD

      Affiliations

    • Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md
    • ,
  • William T. Shearer, MD, PhD

      Affiliations

    • Pediatric Allergy and Immunology, Texas Children's Hospital, Baylor College of Medicine, Houston, Tex
    • Corresponding Author InformationReprint requests: William T. Shearer, MD, PhD, Department of Allergy and Immunology, Texas Children's Hospital, Baylor College of Medicine, MC FC330.01, 6621 Fannin St, Ste A-380, Houston TX, 77030-2399.
    • ,
  • workshop participants

Received 29 August 2008 ,Revised 11 September 2008 ,Accepted 15 September 2008.

References 

  1. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625–655
  2. Cavazzana-Calvo M, Carlier F, Le Deist F, Morillon E, Taupin P, Gautier D, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood. 2007;109:4575–4581
  3. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006;117:725–738
  4. Malech HL, Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune deficiencies: chronic granulomatous disease and leukocyte adhesion deficiency. Curr Opin Hematol. 2007;14:29–36
  5. Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant. 2008;41:119–126
  6. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2:1366–1369
  7. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet. 1968;2:1364–1366
  8. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61:341–348
  9. Read EJ, Carter CS. T-cell depletion of hematopoietic progenitor cell products for allogeneic transplantation. In:  Sacher RA editors. Cellular therapy: new frontiers in transfusion medicine. Bethesda: American Association of Blood Banks; 2002;p. 29–44
  10. Dvorak CC, Hung G-Y, Horn B, Dunn E, Oon C-Y, Cowan MJ. Megadose CD34+ cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible non-myeloablative transplantation. Biol Blood Marrow Transplant. 2008;14:1125–1133
  11. Barge RMY, Starrenburg CWJ, Falkenburg JHF, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath “in the bag” as T-cell depletion: the Leiden experience. Bone Marrow Transplant. 2006;37:1129–1134
  12. Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508–516
  13. Friedrich W, Goldmann SF, Ebell W, Blutters-Sawatzki R, Gaedicke G, Raghavachar A, et al. Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors. Eur J Pediatr. 1985;144:125–130
  14. Dror Y, Gallagher R, Wara DW, Colombe BW, Merino A, Benkerrou M, et al. Immune reconstitution in severe combined immunodeficiency disease following lectin-treated, T cell depleted haplocompatible bone marrow transplantation. Blood. 1993;81:2021–2030
  15. Smogorzewska EM, Brooks J, Annett G, Kapoor N, Crooks GM, Kohn DB, et al. T cell depleted haploidentical bone marrow transplantation for the treatment of children with severe combined immunodeficiency. Arch Immunol Ther Exp (Warsz). 2000;48:111–118
  16. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872–878
  17. Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361:553–560
  18. Mazzolari E, Forino C, Guerci S, Imberti L, Lanfranchi A, Porta F, et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol. 2007;120:892–899
  19. Grunebaum E, Mazzolari E, Porta F, Dallera D, Atkinson A, Reid B, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA. 2006;295:508–518
  20. Roifman CM, Somech R, Grunebaum E. Matched unrelated bone marrow transplant for T + combined immunodeficiency. Bone Marrow Transplant. 2008;41:947–952
  21. Knutsen AP, Wall DA. Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience. J Clin Immunol. 2000;20:466–476
  22. Eggleston B, Patience M, Edwards S, Adamkiewicz T, Buchanan GR, Davies SC, et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol. 2007;136:673–676
  23. Gurney JG, Ness KK, Rosenthal J, Forman SJ, Bhatia S, Baker KS. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the bone marrow transplant survivor study. Cancer. 2006;106:1402–1408
  24. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings of the International Bone Marrow Transplant Registry and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001;7:473–485
  25. Booth C, Ribeil JA, Audat F, Dal-Cortivo L, Veys PA, Thrasher AJ, et al. CD34+ stem cell top-ups without conditioning after initial haematopoietic stem cell transplantation for correction of incomplete haematopoietic and immunological recovery in severe congenital immunodeficiencies. Br J Haematol. 2006;135:533–537
  26. Horn B, Viele M, Mentzer W, Mogck N, DeSantes K, Cowan MJ. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant. 1999;24:1009–1013
  27. Chan K, Puck JM. Development of population–based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005;115:391–398
  28. Puck JM SCID Newborn Screening Working Group. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol. 2007;120:760–768
  29. Li L, Moshous D, Zhou Y, Wang J, Xie G, Salido E, et al. A founder mutation in Artemis, an SNM1-like protein, causes severe combined immunodeficiency disease in Athabascan-speaking Native Americans. J Immunol. 2002;168:6323–6329
  30. Conley ME, Saragoussi D, Notarangelo L, Etzioni A, Casanova J-L. PAGID (Pan-American Group for Immunodeficiencies), ESID (European Society for Immunodeficiencies). An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol. 2003;109:272–277
  31. Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111:e622–e627
  32. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125:876–885
  33. Filipovich AH, Stone JV, Tomany SC, Ireland M, Kollman C, Pelz CJ, et al. Impact of donor type on outcome of bone marrow transplantation for Wiscott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97:1598–1603
  34. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28:1013–1018
  35. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, Schulz A, Thrasher AJ, Mazzolari E, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111:439–445
  36. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol. 2008;126:155–164
  37. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344:881–888
  38. Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 2002;100:4344–4350
  39. Petersdorf EW. Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol. 2008;20:1–6
  40. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced intensity conditioning regimen. Blood. 2005;105:879–885

 Disclosure of potential conflict of interest: M. J. Cowan has received research support from the March of Dimes and Enzo Therapeutics. J. M. Puck has received research support from USIDNET and has provided legal consultation on primary immunodeficiency. K. R. Schultz has received research support from the National Cancer Institute and the Leukemia and Lymphoma Society and has served as an expert witness for DOIL BioPharma. R. H. Buckley has received research support from the National Institutes of Health. N. R. Kamani has received research support from the Pediatric Blood and Marrow Transplant Consortium/Children's Oncology Group and has served as a member of the National Marrow Donor Program. R. J. O'Reilly has received research support from the National Institutes of Health and owns stock in Calibrant. R. Parkman has received research support from the National Institutes of Health. K. E. Sullivan has received research support from the National Institutes of Health and USIDNET, has served as an expert witness for Contocor-Psorusis, and has consulting arrangements with the Immune Deficiency Foundation. The rest of the authors have declared that they have no conflict of interest.

 Report of a workshop sponsored by the Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, and the Office of Rare Diseases, National Institutes of Health, Bethesda, Md, May 12-13, 2008.

 The opinions expressed are those of the authors and do not represent the position of the National Institute of Allergy and Infectious Diseases, the Office of Rare Diseases, the National Institutes of Health, or the US Government.

PII: S0091-6749(08)01841-1

doi: 10.1016/j.jaci.2008.09.045

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 6 , Pages 1087-1096 , December 2008

Article Tools